Trade Conquest

Subscribe Now

| ADTX 0.0127 -2.31% | SOXS 4.72 -5.03% | SPCX 160.95 19.22% | DFNS 0.233 -9.20% | BITO 8.65 0.12% | RUBI 0.4676 -24.62% | TZA 4.16 -2.58% | CAST 1.55 140.68% | AAL 14.98 2.25% | INTC 124.57 6.51% | SPCE 3.91 -31.76% | SHFS 0.276 16.46% | SRXH 0.148 17.65% | NOK 14.795 5.00% | NVDA 205.19 0.16% | BYAH 1.47 40.00% | SPDN 8.81 -0.45% | TQQQ 77.52 1.99% | TSLL 13.59 3.58% | PAVS 0.208 -28.28% | CPOP 0.195 -81.43% | SMCI 30.46 -4.72% | CUPR 3.97 64.73% | VSME 1.69 52.25% | YYGH 0.119 -3.25% | SQQQ 40.04 -1.93% | RKLB 102.39 -10.79% | TSLA 406.43 1.82% | NVD 5.02 -0.40% | WOK 0.0753 -17.70% | SPY 741.75 0.54% | ASTS 82.41 -15.53% | KEEL 5.59 1.27% | ONDS 9.33 -5.09% | SPYM 87.06 0.25% | AMZN 238.55 -1.23% | XLF 53.34 1.37% | SATS 114.08 -10.97% | QQQ 721.34 0.59% | SOFI 16.58 -0.54% | PLUG 2.76 -2.47% | SOXL 234.68 4.77% | GRAB 3.3 -1.49% | DRIP 4.74 -2.47% | AMC 2.34 2.63% | IREN 59.77 5.40% | HKIT 0.5025 -10.11% | RKLZ 3.01 21.37% | RZLV 2.68 5.93% | MARA 14.08 3.45%

Truist Raises Centene Price Target On Improving Margin Outlook

Truist Securities increased its price target on Centene (NYSE: CNC) to $49 from $47 while maintaining a Buy rating, citing constructive discussions with management and improving margin prospects across segments.

The firm highlighted expected Marketplace margin expansion in 2026 and anticipated progress in Medicaid during the second half of 2025, supported by initiatives designed to stabilize the health benefits ratio in 2026. Medicare Advantage remains on track toward breakeven, while 2026 Part D margins are assumed to remain prudent.

Truist stated it continues to see meaningful opportunities to unlock earnings power across Centene’s business and reiterated its positive outlook on the stock.

Published on: February 25, 2026

More news